Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 7/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20602162 | 0.79 | IRAK4 (0.38) | CA1CA2CA9IDO1TDO2 | |
| SCHEMBL26906352 | 0.77 | MAP4K4 (0.41) | HIF1APIK3CDPIK3CAPIK3CGPDGFRB | |
| SCHEMBL3308241 | 0.76 | PIK3CG (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGCA1 | |
| SCHEMBL20620666 | 0.75 | LIPG (0.34) | HIF1AIRAK4 | |
| SCHEMBL31458748 | 0.75 | MAPK1 (0.35) | IRAK4 | |
| SCHEMBL31489632 | 0.74 | IRAK4 (0.35) | IDO1TDO2IRAK4 | |
| SCHEMBL20839881 | 0.72 | TDP2 (0.56) | TDP2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL935986 | 0.72 | PIK3CG (0.53) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL27183790 | 0.71 | BACE1 (0.43) | — | |
| SCHEMBL24303465 | 0.71 | BACE1 (0.44) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | TDP2 1113/4885HIF1A 3603/4885PIK3CD 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.